Baxter Corporation, the Canadian subsidiary of Baxter International, is investing $10 million to build a new facility in Mississauga, Ontario for its centralized intravenous admixing Pharmacy Service (CIVA). Triple the size of the current facility, the new Baxter CIVA Pharmacy Service will expand Baxter's ability to provide Canadian hospitals, clinics, and other care facilities for ready-to-administer intravenous (IV) admixtures, including chemotherapy, high-alert medications, and anti-infectives. 

Baxter's new CIVA facility will double its number of clean rooms available to support customized requirements for hazardous and non-hazardous IV admixing. The company anticipates expanding the workforce by approximately 25 positions over the next few years. Additionally, the new CIVA will include a new training facility through which Baxter will partner with professional organizations, academia, and hospital pharmacists and technicians to support their certification requirements and help maintain their skillset in IV admixing. The company expects to open and transition operations to its new CIVA facility in October 2015.

Source: Baxter Corporation